ORY Oryzon Genomics S.A.

BME · ES · Healthcare · Biotechnology · oryzon.com

2.708EUR-1.02%Mkt Cap: 241.24M $P/E: —Today

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap241.24M USD

Enterprise Value225.97M USD

Revenue (TTM)16.75M USD

Gross Profit11.58M USD

Net Income (TTM)-2.83M USD

Revenue/Share0.20 EUR

Last Price2.708 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees46

CountryES

SectorHealthcare

IndustryBiotechnology

ISINES0167733015

Valuation

P/E (Trailing)—

P/E (Forward)303.56

PEG—

EV/EBITDA-35.59

EV/Revenue13.49

P/S14.53

P/B1.77

EPS (TTM)-0.03

EPS (Forward)0.01

52W Range

2.6008% of range4.020

52W High4.020 EUR

52W Low2.600 EUR

Profitability

Gross Margin97.75%

Oper. Margin30.77%

EBITDA Margin-37.91%

Profit Margin-15.76%

ROE-2.21%

ROA-1.80%

Growth

Revenue Growth106.00%

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.56M USD

CapEx (TTM)12.00M USD

FCF Margin-106.21%

FCF Yield-7.37%

Net Debt-4.23M USD

Net Debt/EBITDA0.67

Balance Sheet

Debt/Equity0.06

Current Ratio1.60

Quick Ratio1.59

Book Value/Sh1.54 EUR

Cash/Share0.19 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)7.133 EUR

Upside (mean)+163.4%

Target Range4.200 EUR – 12.00 EUR

4.200+163.4% to mean12.00

# Analysts3

Ownership

Shares Out.81.96M

Float61.45M

Insiders20.97%

Institutions1.82%

Technical

SMA 502.831 (-4.3%)

SMA 2002.954 (-8.3%)

Beta0.44

S&P 52W Chg14.58%

Avg Vol (30d)107.20K

Avg Vol (10d)129.91K

Technical Indicators

RSI (14)42.3

MACD-0.0242

MACD Signal-0.0247

MACD Hist.+0.0005

BB Upper2.829 EUR

BB Middle2.774 EUR

BB Lower2.719 EUR

BB Width3.95%

ATR (14)0.0571 EUR

Vol Ratio (20d)0.85x